Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 278 clinical trials
featured
  • 614 views
  • 08 Nov, 2020
  • 1 location
featured
ACNS0822: A Randomized, Phase II/III Study of Vorinotat (IND#71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND#7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas

ACNS0822: A Randomized, Phase II/III Study of Vorinotat (IND#71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND#7921) and Local Irradiation Followed by

  • 66 views
  • 08 Nov, 2020
  • 1 location
featured
  • 144 views
  • 25 Mar, 2021
  • 1 location
featured
CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

  • 176 views
  • 08 Nov, 2020
  • 1 location
featured
ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

  • 254 views
  • 08 Nov, 2020
  • 1 location
featured
ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized

  • 106 views
  • 08 Nov, 2020
  • 1 location
Efficacy and Safety of Olaparib Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with Fluorouracil (5-FU) in participants with unresectable or metastatic

solid tumour
chemotherapy regimen
bevacizumab
oxaliplatin
fluorouracil
  • 10 views
  • 20 Jun, 2021
  • 115 locations
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in

  • 57 views
  • 14 May, 2021
  • 54 locations
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.

bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

  • 84 views
  • 20 Jun, 2021
  • 288 locations
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy nave pediatric patients with progressive Low

glomerular filtration rate
neutrophil count
progressive disease
platelet count
corticosteroids
  • 0 views
  • 24 Jan, 2021
  • 24 locations